Track record · closed signal

Avantor, Inc. (AVTR) — closed signal from July 22, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 20, 2025 — +16.3% at the close.

Predicted vs. what happened

AVTR price · publication thesis → realized outcomesplit-adjusted

$12.70 – $13.40Entry zone — fair-value band

$13.06Published — price the day we called it

$17.62Target — the price the thesis aimed for

$15.25Peak — highest point inside the window, not a realized return

$15.18Window close — end-of-window price, context only

What happened

Partial

Reached 48% of the predicted growth at its peak, without hitting the target.

At window close

+16.3%

realized, from the publication price to the last close inside the window

Peak gain

+16.8%

peak, from the publication price — not a realized return

S&P 500, same window

+7%

SPY over the identical days, dividend-adjusted

Window close

$15.18

last close inside the window, ended October 20, 2025

Peak price

$15.25

peak on October 20, 2025 — not a realized return

Days to target

—

The thesis — published July 22, 2025

Predicted growth

+35%

over the measurement window

Target price

$17.62

the price the thesis aimed for

Entry zone

$12.70 – $13.40

the fair-value band we waited for

Price at publication

$13.06

published July 22, 2025

Confidence

73%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

After falling 39% this year and another 8% when the old boss left, Avantor’s shares are now priced much cheaper than similar companies. The new boss, Emanuel Ligner, turned his last company into a star seller of lab supplies, so people hope he can do the same here. Recent data show orders for lab gear may be picking up again. The 8/7 earnings call is the first chance to hear his plan, and if his outlook is steady the stock could climb toward $17 within three months.

Primary drivers

New leader from Cytiva could speed up growth in supplies for cell and gene work.
Share price at 12× profits while peers sit at 18× may rise as investors notice the gap.
When new-order index tops 50, lab tool companies have often bounced soon after.
First earnings call on 8/7 lets the team share a clearer plan, which can lift mood.

How it played out

AVTR: the target was not reached

Lyra published AVTR at $13.06 on 2025-07-22, with a short-term view for 35% growth toward $17.62 within three months. The thesis pointed to a new leader from Cytiva, a share price at 12x profits while peers sat at 18x, a new-order index above 50, and the 8/7 earnings call as a chance for a clearer plan.

Inside the window, AVTR rose but stayed below the target. The peak was $15.25 on 2025-10-20, with a peak gain of 16.8%. It ended at $15.18. The thesis partially played out, but the published target was missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AVTR signals